Business Description
West Pharmaceutical Services Inc
NAICS : 339112
SIC : 3841
ISIN : US9553061055
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.76 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 0.37 | |||||
Interest Coverage | 78.6 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 20.03 | |||||
Beneish M-Score | -2.71 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.4 | |||||
3-Year EBITDA Growth Rate | 17.9 | |||||
3-Year EPS without NRI Growth Rate | 19.3 | |||||
3-Year FCF Growth Rate | 11.9 | |||||
3-Year Book Growth Rate | 16.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 6.87 | |||||
Future 3-5Y Total Revenue Growth Rate | 6.39 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 23.7 | |||||
9-Day RSI | 31.67 | |||||
14-Day RSI | 37.88 | |||||
6-1 Month Momentum % | 6.26 | |||||
12-1 Month Momentum % | 9.64 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.88 | |||||
Quick Ratio | 2.24 | |||||
Cash Ratio | 1.27 | |||||
Days Inventory | 87.32 | |||||
Days Sales Outstanding | 64 | |||||
Days Payable | 45.29 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.22 | |||||
Dividend Payout Ratio | 0.1 | |||||
3-Year Dividend Growth Rate | 5.8 | |||||
Forward Dividend Yield % | 0.22 | |||||
5-Year Yield-on-Cost % | 0.28 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 1.93 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 38.28 | |||||
Operating Margin % | 23.98 | |||||
Net Margin % | 20.12 | |||||
FCF Margin % | 13.2 | |||||
ROE % | 21.26 | |||||
ROA % | 15.96 | |||||
ROIC % | 23.46 | |||||
ROC (Joel Greenblatt) % | 36.53 | |||||
ROCE % | 22.34 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 46.72 | |||||
Forward PE Ratio | 47.39 | |||||
PE Ratio without NRI | 45.57 | |||||
Shiller PE Ratio | 75.93 | |||||
Price-to-Owner-Earnings | 53.84 | |||||
PEG Ratio | 2.07 | |||||
PS Ratio | 9.4 | |||||
PB Ratio | 9.39 | |||||
Price-to-Tangible-Book | 9.55 | |||||
Price-to-Free-Cash-Flow | 66.77 | |||||
Price-to-Operating-Cash-Flow | 35.66 | |||||
EV-to-EBIT | 36.62 | |||||
EV-to-Forward-EBIT | 37.04 | |||||
EV-to-EBITDA | 30.67 | |||||
EV-to-Forward-EBITDA | 30.4 | |||||
EV-to-Revenue | 8.78 | |||||
EV-to-Forward-Revenue | 8.62 | |||||
EV-to-FCF | 63.99 | |||||
Price-to-Projected-FCF | 3.84 | |||||
Price-to-DCF (Earnings Based) | 1.44 | |||||
Price-to-DCF (FCF Based) | 2.11 | |||||
Price-to-Median-PS-Value | 1.8 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.96 | |||||
Price-to-Graham-Number | 4.34 | |||||
Price-to-Net-Current-Asset-Value | 26.66 | |||||
Earnings Yield (Greenblatt) % | 2.74 | |||||
FCF Yield % | 1.59 | |||||
Forward Rate of Return (Yacktman) % | 21.21 |